Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Informed Consent | 21 | 2019 | 51 | 4.340 |
Why?
|
| Human Experimentation | 13 | 2019 | 17 | 3.100 |
Why?
|
| Research Subjects | 11 | 2019 | 28 | 2.350 |
Why?
|
| Decision Making | 9 | 2019 | 180 | 1.980 |
Why?
|
| Disclosure | 8 | 2019 | 36 | 1.520 |
Why?
|
| Consent Forms | 5 | 2019 | 8 | 1.500 |
Why?
|
| Clinical Trials as Topic | 12 | 2015 | 298 | 1.450 |
Why?
|
| Biomedical Research | 8 | 2015 | 153 | 1.250 |
Why?
|
| Nanomedicine | 3 | 2019 | 17 | 1.210 |
Why?
|
| Ethics Committees, Research | 7 | 2018 | 19 | 1.180 |
Why?
|
| Ethics, Research | 10 | 2018 | 25 | 1.150 |
Why?
|
| Therapeutic Misconception | 3 | 2019 | 3 | 0.990 |
Why?
|
| Moral Obligations | 2 | 2016 | 4 | 0.980 |
Why?
|
| Personal Autonomy | 3 | 2014 | 9 | 0.960 |
Why?
|
| Physicians | 3 | 2016 | 134 | 0.960 |
Why?
|
| Physician-Patient Relations | 3 | 2019 | 169 | 0.890 |
Why?
|
| Humans | 49 | 2019 | 29123 | 0.760 |
Why?
|
| Genetic Testing | 2 | 2013 | 90 | 0.750 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 15 | 0.690 |
Why?
|
| Conflict of Interest | 4 | 2013 | 39 | 0.690 |
Why?
|
| Physician's Role | 1 | 2019 | 38 | 0.670 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2013 | 464 | 0.670 |
Why?
|
| Nanoparticles | 1 | 2019 | 48 | 0.660 |
Why?
|
| Gene Transfer Techniques | 8 | 2012 | 69 | 0.660 |
Why?
|
| Tracheostomy | 1 | 2018 | 28 | 0.650 |
Why?
|
| United States | 18 | 2018 | 3632 | 0.610 |
Why?
|
| Caregivers | 1 | 2018 | 94 | 0.600 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 251 | 0.590 |
Why?
|
| Patient Rights | 2 | 2016 | 14 | 0.580 |
Why?
|
| Conscience | 1 | 2016 | 2 | 0.560 |
Why?
|
| Refusal to Treat | 1 | 2016 | 3 | 0.560 |
Why?
|
| Abortion, Induced | 1 | 2016 | 5 | 0.560 |
Why?
|
| Dissent and Disputes | 1 | 2015 | 4 | 0.530 |
Why?
|
| Bioethical Issues | 1 | 2015 | 4 | 0.530 |
Why?
|
| Cultural Diversity | 1 | 2015 | 19 | 0.520 |
Why?
|
| Creatinine | 1 | 2014 | 174 | 0.490 |
Why?
|
| Advisory Committees | 5 | 2019 | 32 | 0.480 |
Why?
|
| Electronic Health Records | 1 | 2014 | 118 | 0.460 |
Why?
|
| Brain Concussion | 1 | 2014 | 60 | 0.460 |
Why?
|
| Football | 1 | 2014 | 73 | 0.450 |
Why?
|
| Research | 3 | 2007 | 72 | 0.450 |
Why?
|
| Confidentiality | 1 | 2013 | 22 | 0.450 |
Why?
|
| Sports Medicine | 1 | 2013 | 23 | 0.430 |
Why?
|
| Systems Integration | 1 | 2012 | 8 | 0.430 |
Why?
|
| Health Services Administration | 1 | 2012 | 3 | 0.430 |
Why?
|
| Attitude to Health | 1 | 2013 | 148 | 0.430 |
Why?
|
| Athletes | 1 | 2013 | 65 | 0.430 |
Why?
|
| Animal Experimentation | 1 | 2011 | 6 | 0.410 |
Why?
|
| Hospitalization | 1 | 2014 | 417 | 0.410 |
Why?
|
| Communicable Diseases | 1 | 2011 | 19 | 0.400 |
Why?
|
| Primates | 1 | 2011 | 100 | 0.400 |
Why?
|
| Patient Selection | 6 | 2019 | 257 | 0.390 |
Why?
|
| Motivation | 2 | 2009 | 102 | 0.390 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2005 | 14 | 0.390 |
Why?
|
| Altruism | 2 | 2009 | 7 | 0.380 |
Why?
|
| Tissue Engineering | 1 | 2015 | 608 | 0.360 |
Why?
|
| Kidney Failure, Chronic | 1 | 2013 | 518 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2013 | 836 | 0.320 |
Why?
|
| Patient Participation | 3 | 2007 | 62 | 0.310 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2007 | 18 | 0.300 |
Why?
|
| Risk Assessment | 7 | 2012 | 1306 | 0.300 |
Why?
|
| Attitude of Health Personnel | 2 | 2010 | 162 | 0.280 |
Why?
|
| Terminology as Topic | 1 | 2005 | 62 | 0.250 |
Why?
|
| Researcher-Subject Relations | 1 | 2004 | 3 | 0.240 |
Why?
|
| Vulnerable Populations | 1 | 2004 | 25 | 0.240 |
Why?
|
| Genomics | 2 | 2015 | 82 | 0.230 |
Why?
|
| Germ Cells | 1 | 2003 | 11 | 0.230 |
Why?
|
| Female | 8 | 2019 | 18173 | 0.220 |
Why?
|
| Diffusion of Innovation | 1 | 2003 | 29 | 0.220 |
Why?
|
| Government Regulation | 5 | 2012 | 35 | 0.220 |
Why?
|
| Organ Transplantation | 3 | 2015 | 65 | 0.210 |
Why?
|
| Risk | 2 | 2013 | 289 | 0.200 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2005 | 18 | 0.190 |
Why?
|
| Adult | 5 | 2019 | 8426 | 0.190 |
Why?
|
| Neonatal Screening | 1 | 2019 | 6 | 0.180 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2019 | 4 | 0.180 |
Why?
|
| Fragile X Syndrome | 1 | 2019 | 5 | 0.180 |
Why?
|
| Public Health | 1 | 2019 | 73 | 0.170 |
Why?
|
| Disabled Children | 1 | 2018 | 18 | 0.160 |
Why?
|
| Therapeutic Human Experimentation | 4 | 2013 | 4 | 0.160 |
Why?
|
| Death | 1 | 2018 | 41 | 0.160 |
Why?
|
| Literature | 1 | 2018 | 1 | 0.160 |
Why?
|
| Home Care Services | 1 | 2018 | 48 | 0.160 |
Why?
|
| Genetic Vectors | 2 | 2012 | 118 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2018 | 142 | 0.160 |
Why?
|
| Embryonic Stem Cells | 2 | 2015 | 30 | 0.160 |
Why?
|
| Parents | 1 | 2018 | 120 | 0.150 |
Why?
|
| Child | 2 | 2018 | 2219 | 0.140 |
Why?
|
| Blood Substitutes | 2 | 2006 | 3 | 0.140 |
Why?
|
| Hemoglobins | 2 | 2006 | 42 | 0.140 |
Why?
|
| Clinical Medicine | 1 | 2015 | 13 | 0.140 |
Why?
|
| Attitude | 1 | 2015 | 37 | 0.140 |
Why?
|
| Ethics, Medical | 1 | 2015 | 16 | 0.140 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2015 | 11 | 0.140 |
Why?
|
| Male | 6 | 2019 | 17815 | 0.130 |
Why?
|
| Comprehension | 2 | 2005 | 19 | 0.130 |
Why?
|
| Uncertainty | 2 | 2012 | 12 | 0.130 |
Why?
|
| Infant | 1 | 2018 | 969 | 0.130 |
Why?
|
| European Union | 2 | 2011 | 6 | 0.130 |
Why?
|
| Child, Preschool | 1 | 2018 | 1167 | 0.130 |
Why?
|
| Genetic Research | 2 | 2012 | 2 | 0.120 |
Why?
|
| Public Policy | 2 | 2002 | 34 | 0.120 |
Why?
|
| Organizational Policy | 1 | 2014 | 20 | 0.120 |
Why?
|
| Organizational Culture | 1 | 2014 | 26 | 0.120 |
Why?
|
| Family Health | 1 | 2013 | 78 | 0.120 |
Why?
|
| Biomedical Technology | 2 | 1991 | 6 | 0.120 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 165 | 0.120 |
Why?
|
| Health Policy | 2 | 2019 | 80 | 0.110 |
Why?
|
| Pregnancy | 1 | 2016 | 815 | 0.110 |
Why?
|
| Quality of Life | 1 | 2018 | 816 | 0.110 |
Why?
|
| Middle Aged | 4 | 2018 | 10834 | 0.110 |
Why?
|
| Stroke | 1 | 2018 | 548 | 0.110 |
Why?
|
| Emergency Service, Hospital | 2 | 2006 | 430 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 203 | 0.110 |
Why?
|
| Retroviridae | 1 | 2012 | 25 | 0.110 |
Why?
|
| Professional Role | 1 | 2012 | 19 | 0.100 |
Why?
|
| Risk Management | 1 | 2012 | 29 | 0.100 |
Why?
|
| Young Adult | 1 | 2018 | 2402 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 83 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 154 | 0.100 |
Why?
|
| Social Perception | 1 | 2011 | 21 | 0.100 |
Why?
|
| Animals | 2 | 2015 | 7299 | 0.100 |
Why?
|
| Patient Care | 2 | 2007 | 33 | 0.100 |
Why?
|
| Diet | 1 | 2013 | 355 | 0.100 |
Why?
|
| Environmental Exposure | 1 | 2012 | 87 | 0.100 |
Why?
|
| Renal Dialysis | 1 | 2013 | 260 | 0.100 |
Why?
|
| Adolescent | 1 | 2018 | 3255 | 0.100 |
Why?
|
| Tissue Banks | 1 | 2010 | 16 | 0.090 |
Why?
|
| Internationality | 1 | 2010 | 21 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 150 | 0.090 |
Why?
|
| European Continental Ancestry Group | 1 | 2013 | 1131 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2019 | 599 | 0.080 |
Why?
|
| Exercise | 1 | 2013 | 592 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 180 | 0.080 |
Why?
|
| Europe | 1 | 2008 | 77 | 0.080 |
Why?
|
| Insurance Selection Bias | 1 | 2007 | 9 | 0.080 |
Why?
|
| Research Design | 3 | 2018 | 286 | 0.070 |
Why?
|
| African Americans | 1 | 2013 | 1373 | 0.070 |
Why?
|
| Financial Support | 1 | 1986 | 6 | 0.070 |
Why?
|
| Financing, Government | 1 | 1986 | 10 | 0.070 |
Why?
|
| Health Care Rationing | 1 | 1986 | 11 | 0.070 |
Why?
|
| Emergency Treatment | 1 | 2006 | 42 | 0.070 |
Why?
|
| Resource Allocation | 1 | 1986 | 10 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2006 | 134 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2006 | 110 | 0.070 |
Why?
|
| Mass Screening | 1 | 2007 | 223 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 1986 | 391 | 0.060 |
Why?
|
| State Government | 2 | 1986 | 31 | 0.060 |
Why?
|
| Emergency Medical Services | 1 | 2006 | 157 | 0.060 |
Why?
|
| United States Food and Drug Administration | 3 | 2006 | 44 | 0.060 |
Why?
|
| Cognition | 1 | 2007 | 526 | 0.060 |
Why?
|
| Ethical Review | 1 | 2003 | 2 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2003 | 17 | 0.060 |
Why?
|
| Prognosis | 1 | 2007 | 1362 | 0.060 |
Why?
|
| Liver | 1 | 1986 | 464 | 0.050 |
Why?
|
| DNA, Recombinant | 1 | 2002 | 9 | 0.050 |
Why?
|
| Federal Government | 1 | 2002 | 10 | 0.050 |
Why?
|
| Models, Organizational | 1 | 2002 | 17 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2002 | 29 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2002 | 48 | 0.050 |
Why?
|
| Aged | 3 | 2018 | 9492 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2002 | 68 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2004 | 231 | 0.050 |
Why?
|
| Legislation as Topic | 1 | 1979 | 5 | 0.050 |
Why?
|
| Beneficence | 2 | 2007 | 5 | 0.040 |
Why?
|
| Self-Help Groups | 1 | 2019 | 6 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 61 | 0.040 |
Why?
|
| Social Control, Formal | 2 | 1991 | 7 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 175 | 0.040 |
Why?
|
| Internet | 1 | 2019 | 156 | 0.040 |
Why?
|
| Social Responsibility | 2 | 2012 | 13 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 1991 | 159 | 0.040 |
Why?
|
| Heart | 2 | 1991 | 162 | 0.040 |
Why?
|
| Data Collection | 2 | 2010 | 163 | 0.040 |
Why?
|
| Zygote | 1 | 2015 | 1 | 0.030 |
Why?
|
| Japan | 1 | 2015 | 15 | 0.030 |
Why?
|
| North Carolina | 1 | 2019 | 1423 | 0.030 |
Why?
|
| Genome, Human | 1 | 2015 | 129 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2015 | 149 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 2021 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2109 | 0.030 |
Why?
|
| United States Office of Research Integrity | 1 | 2013 | 1 | 0.030 |
Why?
|
| Pulmonary Surfactants | 1 | 2013 | 13 | 0.030 |
Why?
|
| Oxygen | 1 | 2013 | 139 | 0.030 |
Why?
|
| Negotiating | 1 | 2012 | 8 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2012 | 6 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2012 | 26 | 0.030 |
Why?
|
| Congenital, Hereditary, and Neonatal Diseases and Abnormalities | 1 | 1991 | 1 | 0.020 |
Why?
|
| Wrongful Life | 1 | 1991 | 1 | 0.020 |
Why?
|
| Third-Party Consent | 1 | 1991 | 2 | 0.020 |
Why?
|
| Legislation, Drug | 1 | 2011 | 7 | 0.020 |
Why?
|
| Terminally Ill | 1 | 1991 | 2 | 0.020 |
Why?
|
| Paternalism | 1 | 1991 | 3 | 0.020 |
Why?
|
| Parental Consent | 1 | 1991 | 3 | 0.020 |
Why?
|
| Freedom | 1 | 1991 | 4 | 0.020 |
Why?
|
| Patient Advocacy | 1 | 2011 | 13 | 0.020 |
Why?
|
| Coercion | 1 | 1991 | 5 | 0.020 |
Why?
|
| Technology Assessment, Biomedical | 1 | 1991 | 10 | 0.020 |
Why?
|
| Jurisprudence | 1 | 1991 | 7 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 1991 | 11 | 0.020 |
Why?
|
| Drugs, Investigational | 1 | 1991 | 5 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 1991 | 18 | 0.020 |
Why?
|
| Reference Standards | 1 | 1991 | 30 | 0.020 |
Why?
|
| Equipment and Supplies | 1 | 1991 | 15 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1991 | 39 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 1991 | 15 | 0.020 |
Why?
|
| Malpractice | 1 | 1991 | 20 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 16 | 0.020 |
Why?
|
| General Surgery | 1 | 1991 | 81 | 0.020 |
Why?
|
| Heart Diseases | 1 | 1991 | 99 | 0.020 |
Why?
|
| Biological Products | 1 | 2011 | 66 | 0.020 |
Why?
|
| Liability, Legal | 1 | 2009 | 28 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2012 | 224 | 0.020 |
Why?
|
| Cell Line | 1 | 2010 | 450 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 1991 | 239 | 0.020 |
Why?
|
| Goals | 1 | 2007 | 36 | 0.020 |
Why?
|
| Solutions | 1 | 2006 | 26 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2006 | 24 | 0.020 |
Why?
|
| Shock, Hemorrhagic | 1 | 2006 | 23 | 0.020 |
Why?
|
| Economics | 1 | 1986 | 7 | 0.020 |
Why?
|
| Massachusetts | 1 | 1986 | 28 | 0.020 |
Why?
|
| Ambulances | 1 | 2006 | 12 | 0.020 |
Why?
|
| Mass Media | 1 | 1986 | 12 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2007 | 222 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2006 | 64 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2006 | 95 | 0.020 |
Why?
|
| Nontherapeutic Human Experimentation | 1 | 2005 | 1 | 0.020 |
Why?
|
| Medicaid | 1 | 1986 | 83 | 0.020 |
Why?
|
| Hospitals | 1 | 1986 | 89 | 0.020 |
Why?
|
| Poverty | 1 | 1986 | 99 | 0.020 |
Why?
|
| Insurance, Health | 1 | 1986 | 91 | 0.020 |
Why?
|
| Research Personnel | 1 | 2004 | 13 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2005 | 249 | 0.020 |
Why?
|
| Communication | 1 | 2004 | 122 | 0.010 |
Why?
|
| Ethics Committees | 1 | 1979 | 1 | 0.010 |
Why?
|
| New York | 1 | 1979 | 18 | 0.010 |
Why?
|
| California | 1 | 1979 | 60 | 0.010 |
Why?
|
| Neoplasms | 1 | 2004 | 611 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 3719 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 1017 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2004 | 3101 | 0.010 |
Why?
|